Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $18 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $20 from $16 at H.C. Wainwright
- Amylyx Pharmaceuticals Reports Strong Q3 2025 Results
- Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges
- Buy Rating for Amylyx Pharmaceuticals: Strong Financial Health and Promising Pipeline Developments
- Buy Rating for Amylyx Pharmaceuticals: Promising Phase III Study and Market Potential for Avexitide